[VSsupport]

TOKYO, Nov 10 (Reuters) - Astellas Pharma, Japan's No.2 drugmaker, said on Tuesday it will buy the rights to develop and sell U.S. firm Ironwood Pharmaceuticals' drug for irritable bowel syndrome in Japan and other parts of Asia. Astellas will pay $75 million upfront to develop linaclotide, now in Phase III trials in the United States to treat irritable bowel syndrome with constipation and ...View the full article